Segawa Yoshihiko

Affiliation and department：
Research theme for competitive and other funds (1)：

2017 - 2022 An Open Label Phase II Study on the efficacy of Nivolumab(ONO-4538) in Japanese Subjects with cancer of unknown primary (CUP) (NivoCUP)

Papers (10)：

Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2022. 33. 216-226
Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka, Masato Nakamura, Mitsugu Kochi, Akinori Takagane, Ken Shimada, Tadamichi Denda, Yoshihiko Segawa, Hiroaki Tanioka, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. British Journal of Cancer. 2020. 123. 10. 1490-1495
Hidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, Kohei Akiyoshi, Yoshihiko Segawa, Hiroki Ued, Yasuo Iwamoto, Chihiro Kondoh, Koji Matsumoto, Shin Takahashi, et al. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: a Nonrandomized Phase 2 Clinical Trial. JAMA Oncology. 2020. 6. 12. 1-9
Sunakawa Y, Mogushi K, Lenz H, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, et al. Tumor sideness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer. Molecular Cancer Therapeutics. 2018. 17. 12. 2788-2795
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, et al. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Gastric Cancer. 2018. 21. 421-427

ｍore...

Books (4)：

がん救急がん治療認定医教育セミナーテキスト第10版日本がん治療認定医機構教育委員会編集
日本がん治療認定医機構教育委員会 2016
前立腺がん:前立腺がんに対してCombined androgen blockade (CAB)は去勢単独よりも推奨されるか? EBMがん化学療法・分子標的治療法 2015-2016 監修:西條長宏、編集:朴成和、大江裕一郎、南博信、直江知樹、2015、中外医学社(東京)
中外医学社 2015
がん救急がん治療認定医教育セミナーテキスト第9版日本がん治療認定医機構教育委員会編集
日本がん治療認定医機構教育委員会 2015
がん外来化学療法の安全性と効率化がん化学療法チームマネジメント:埼玉医科大学国際医療センターでの検証と未来像監修:小山勇、編集:佐伯俊昭、2015、医学と看護社(東京)
医学と看護社 2015

Lectures and oral presentations (7)：

Phase II Trial of Site-Specific Treatment Based on Gene Expression and Mutation Profiling by NGS for Patients with Cancer of Unknown Primary (CUP)
(第18回日本臨床腫瘍学会学術集会 2021)
A phase II study on the efficacy of Nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP)
(第18回日本臨床腫瘍学会学術集会 2021)
NivoCUP: An open label phase 2 study on the efficacy of Nivolumab in cancer of unknown primary (CUP)
(Annual Meeting of ASCO 2020 2020)
A phase II study on the efficacy of nivolumab in Japanese patients with cancer of unknown primary (CUP) (NivoCUP).
(2019)
Update on the phase II trial of cetuximab in combination with S-1 and oxaliplatin (SOX) for metastatic colorectal cancer (mCRC).
(2019)

ｍore...

Professional career (1)：

岡山大学医学博士 (岡山大学)

Committee career (3)：

2014/04 - 現在腫瘍内科医会運営委員
2013/08 - 2022/03 日本臨床腫瘍学会教育企画部会委員
2013/08 - 2018/07 日本臨床腫瘍学会新臨床腫瘍学改訂第4及び5版編集委員会委員

Association Membership(s) (9)：

日本臨床腫瘍学会 , International Association for the Study of Lung Cancer , American Society of Clinical Oncology , 日本癌学会 , 日本内科学会 , 日本肺癌学会 , 日本癌治療学会 , 日本呼吸器学会 , 日本呼吸器内視鏡学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page